Stock Events

Stock Events

XORTX Therapeutics 

€2.08
0
+€0.17+8.98% Monday 06:46

Statistics

Day High
2.08
Day Low
2.08
52W High
5.05
52W Low
1.68
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MayExpected
Q4 2025
Next
-0.71
-0.54
-0.38
-0.21
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ANU.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap110.97B
Vertex Pharmaceuticals is involved in developing treatments for cystic fibrosis and other diseases, potentially overlapping with XORTX's focus on kidney diseases and conditions that could have similar treatment approaches.
Aurinia Pharmaceuticals
AUPH
Mkt Cap2.1B
Aurinia Pharmaceuticals focuses on the development of therapies for autoimmune diseases, including lupus nephritis, which could compete with XORTX's kidney-focused therapies.
Akebia Therapeutics
AKBA
Mkt Cap375.03M
Akebia Therapeutics works on treatments for kidney disease and anemia, areas that overlap with XORTX's therapeutic focus, making them direct competitors.
Ardelyx
ARDX
Mkt Cap1.52B
Ardelyx focuses on kidney and cardiovascular diseases, offering treatments that could compete with XORTX's products for similar indications.
Trevena
TRVN
Mkt Cap9,501
Trevena develops therapies for central nervous system disorders but has potential overlap in treatment methodologies that could be applied to conditions XORTX targets.
Outlook Therapeutics
OTLK
Mkt Cap26.05M
Outlook Therapeutics is focused on ocular diseases but represents the broader competition in the biopharmaceutical sector, competing for investment and resources.

About

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Show more...
CEO
Dr. Allen Warren Davidoff Ph.D.
Employees
2
Country
Canada
ISIN
CA98420Q4051

Listings

MU
DE
ANU.MU
STU
DE
ANUA.STU
F
DE
ANU.F
V
CA
XRTX.V

0 Comments

Share your thoughts

FAQ

What is XORTX Therapeutics stock price today?▼
The current price of ANU.MU is €2.08 EUR — it has increased by +8.98% in the past 24 hours. Watch XORTX Therapeutics stock price performance more closely on the chart.
What is XORTX Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange XORTX Therapeutics stocks are traded under the ticker ANU.MU.
Is XORTX Therapeutics stock price growing?▼
ANU.MU stock has risen by +23.51% compared to the previous week, the month change is a +5.6% rise, over the last year XORTX Therapeutics has showed a -45.96% decrease.
When is the next XORTX Therapeutics earnings date?▼
XORTX Therapeutics is going to release the next earnings report on May 14, 2026.
What were XORTX Therapeutics earnings last quarter?▼
ANU.MU earnings for the last quarter are -0.21 EUR per share, whereas the estimation was -0.71 EUR resulting in a +70.08% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does XORTX Therapeutics have?▼
As of April 14, 2026, the company has 2 employees.
In which sector is XORTX Therapeutics located?▼
XORTX Therapeutics operates in the Health & Wellness sector.
When did XORTX Therapeutics complete a stock split?▼
XORTX Therapeutics has not had any recent stock splits.
Where is XORTX Therapeutics headquartered?▼
XORTX Therapeutics is headquartered in Calgary, Canada.